South San Francisco, Calif. — Spruce Biosciences Inc. said it has appointed Eric Jordan as Vice President of Marketing and Tina Gullotta, CPA, as Vice President of Finance and Corporate Controller.
The late-stage biopharmaceutical company said the appointments strengthen its commercial and financial capabilities as it prepares for the potential U.S. Food and Drug Administration approval and commercial launch of tralesinidase alfa enzyme replacement therapy, also known as TA-ERT, for the treatment of Sanfilippo syndrome type B, or MPS IIIB.
“We are delighted to welcome both Eric and Tina, two accomplished leaders with deep biotech experience, to the Spruce executive team,” said Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer of Spruce Biosciences. “Eric brings a proven track record of building rare disease brands and orchestrating successful launches, and Tina brings the finance and accounting expertise critical to operating as a commercial-stage organization. We look forward to working closely with them as we prepare for the potential U.S. FDA approval and commercial launch of TA-ERT.”
Jordan has more than 20 years of strategic marketing experience in the pharmaceutical and biotech industries, with expertise in rare disease launch preparation and execution.
He most recently served as Marketing Team Lead at BridgeBio, where he led marketing and launch planning for encaleret, an investigational treatment for a rare endocrine disorder. Previously, he was Vice President of Marketing at Dompé Pharmaceuticals, where he led the U.S. launch and commercialization of Oxervate for neurotrophic keratitis.
Jordan also held marketing leadership roles at Aimmune Therapeutics and ZS Pharma. Earlier in his career, he worked at Genentech in roles across BioOncology and Nutropin marketing, ultimately serving as Associate Director, Business Unit Operations and Chief of Staff to the senior vice president of sales and marketing for an approximately $2 billion business unit.
He earned an MBA from the Haas School of Business at the University of California, Berkeley, and a bachelor’s degree in marketing from Pennsylvania State University.
Gullotta has more than 25 years of senior finance leadership experience in the life sciences industry, with experience guiding biotechnology companies through clinical growth, capital raises, operational transformation and public-company readiness.
She most recently served as Vice President of Finance at Frontier Medicines Corp., where she led the finance and accounting organization and worked as a strategic partner to the CEO, CFO and board.
Before Frontier, Gullotta served as Vice President of Finance and Chief Accounting Officer at Sunesis Pharmaceuticals, where she oversaw SEC reporting, technical accounting, SOX 404 compliance and treasury, and supported fundraising and capital markets activities.
Earlier, she served as Senior Director and Corporate Controller at Atara Biotherapeutics, where she participated in the company’s IPO and follow-on offerings and led SEC reporting, audit and SOX 404 programs.
Gullotta is a Certified Public Accountant and earned a bachelor’s degree in commerce and accounting from Santa Clara University.
“Spruce is on the cusp of delivering what could be the first disease-modifying treatment option for patients with Sanfilippo Syndrome Type B, and the opportunity to help launch a therapy with this kind of potential impact is exactly what drew me to the team,” said Mr. Jordan. “I look forward to building the marketing foundation needed to bring TA-ERT to the patients and families who have been waiting for it.”
“I am thrilled to join Spruce at such a pivotal moment in the company’s evolution,” said Ms. Gullotta. “I look forward to partnering with the leadership team to scale the finance and accounting organization, strengthen our controls and reporting infrastructure, and support Spruce’s transition to a commercial-stage company.”
